Clinical manifestations are complex and often involve multiple systemic manifestations. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of this disease requires a combination of clinical manifestations, imaging inspections, laboratory tests and pathological active checks.
A comprehensive assessment platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnoses and treatment programs. Individualised development of treatment programs for treatment and management of pulmonary manifestations of HL is often required, including drug therapy, rehabilitation intervention, and regular follow-up to multiple-dimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of HL-related lung fatigue. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.